Insights from 2025 ASCO® GU Annual Meeting

 

Prostate Cancer
08:20

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Summary: SOLAR & SATURN Clinical Trials - Comparing the Progression of De Novo vs. Recurrent PSMA-Defined Oligo-M1 Prostate Cancer Following Systemic Therapy & Tumor-Directed Therapy

FEATURING Amar Kishan
  • 6 views
  • April 12, 2025
04:08

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: TRITON3 Final OS and Safety - Rucaparib vs. Docetaxel or Second-Generation ARPI in mCRPC

FEATURING Alan Bryce
  • 2 views
  • April 11, 2025
11:50

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: Initial Biopsy Results Screening for Inherited Risk of Developing Aggressive Prostate Cancer - PATROL Study

FEATURING Daniel Lee
  • 9 views
  • April 9, 2025
09:57

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: Choice of Androgen Receptor Pathway Inhibitors (ARPi) by Disease Volume and Timing of Metastases in mHSPC

FEATURING Syed Arsalan Ahmed Naqvi
  • 14 views
  • April 9, 2025
12:06

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: Can MRI Accurately Replace Confirmatory Biopsy for Prostate Cancer Patients on Active Surveillance?

FEATURING Matthew Cooperberg
  • 27 views
  • April 2, 2025
  • 1
04:31

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: Age-Related Outcomes of Darolutamide + ADT and Docetaxel in mHSPC: Subgroup Analysis From ARASENS

FEATURING Joan Carles
  • 17 views
  • March 27, 2025
04:02

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: HSD3B1 and OS in Metastatic and Non-Metastatic Prostate Cancer Starting ADT With ENZ or AAP - STAMPEDE Trial

FEATURING Nima Sharifi
  • 13 views
  • March 12, 2025
02:39

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: Impact of BRCA Status in mCRPC Patients Undergoing Abiraterone +/- SBRT - ARTO Trial

FEATURING Giulio Francolini
  • 3 views
  • March 11, 2025
04:03

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: Adrenal Androgens and OS in Men With mCRPC Treated With ENZ or ENZ/AAP - Alliance Trial

FEATURING Nima Sharifi
  • 13 views
  • March 7, 2025
04:12

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: Neoadjuvant Intra-Arterial 177Lu-PSMA-617 in High-Risk Localized or Locally Advanced Prostate Cancer - LUPUS Trial

FEATURING Claudia Kesch
  • 10 views
  • March 7, 2025
05:50

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: Efficacy of 177Lu-PSMA-617 +/- ARPIs for the Treatment of mCRPC - VISION Secondary Analysis

FEATURING Omid Yazdanpanah
  • 105 views
  • March 6, 2025
13:56

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: AI-Derived Tumor Volume From Baseline MRI and Postprostatectomy Outcomes Following Neoadjuvant Hormonal Therapy for High-Risk Prostate Cancer

FEATURING David Yang
  • 7 views
  • March 6, 2025
05:43

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Summary: Advances in Metastatic Prostate Cancer Treatment - AI, Genomics, Radioligand Therapy, and Drug Comparisons

FEATURING Pedro Barata
  • 132 views
  • March 4, 2025
05:59

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: mCRPC Survival Outcomes With 177Lu-PSMA-617 Based on Line of Therapy

FEATURING Nicolas Sayegh
  • 131 views
  • February 25, 2025
09:23

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: The Influence of Boosting Gut Health and Phytochemical-Rich Foods in Men With Prostate Cancer

FEATURING Robert Thomas
  • 231 views
  • February 19, 2025
  • 6
13:52

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: Final Outcomes of the ARNEO Trial - Neoadjuvant Degarelix +/- Apalutamide Before Radical Prostatectomy in High-Risk Prostate Cancer

FEATURING Alexander Giesen
  • 36 views
  • February 18, 2025